Sinovac Biotech (SVA) To Offer 8.65M Shares
Sinovac Biotech Ltd. (Nasdaq: SVA) plans to sell 8,650,000 common shares of the company in an underwritten public offering. Sinovac plans to grant the underwriters an option to purchase up to an additional 1,297,500 common shares to cover overallotments.
Sinovac plans to use the net proceeds of the offering to fund the acquisition and expansion of production facilities, the enhancement of production lines, the research and development of product candidates, the expansion of product pipeline, and general corporate purposes (including an undetermined amount for potential acquisitions).
Sinovac plans to use the net proceeds of the offering to fund the acquisition and expansion of production facilities, the enhancement of production lines, the research and development of product candidates, the expansion of product pipeline, and general corporate purposes (including an undetermined amount for potential acquisitions).
You May Also Be Interested In
- Delcath (DCTH) Prices 13.3M Shares at $1.50/Share, Sees Net Proceeds of $18.4M
- Euroseas (ESEA) commences 13.9M rights offering
- A123 Systems (AONE) Amends Purchase Agreement, Will File 49.6M Common Shelf for Underlying Notes
Create E-mail Alert Related Categories
Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
